Summary
Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding, and infertility. Endometriosis has the potential to disrupt the quality of life of women, leading to emotional distress, loss of work productivity, physical limitations, and social withdrawal.
This report also provides diagnosed incident and prevalent cases of endometriosis segmented by laparoscopy confirmation status (laparoscopy-confirmed or suspected without laparoscopy). The laparoscopy-confirmed diagnosed prevalent cases of endometriosis are further classified according to endometriosis staging system developed by the American Society for Reproductive Medicine (ASRM) into stage I (minimal), stage II (mild), stage III (moderate), and stage IV (severe). In addition, the laparoscopy-confirmed diagnosed prevalent cases of endometriosis are segmented by phenotypes into superficial peritoneal endometriosis (SUP), ovarian endometrioma (OMA), and deeply infiltrating endometriosis (DIE). The laparoscopy-confirmed diagnosed incident and laparoscopy-confirmed diagnosed prevalent cases of endometriosis are further segmented by age.
In the 7MM, GlobalData epidemiologists forecast that the laparoscopy-confirmed diagnosed incident cases of endometriosis will increase from 251,010 cases in 2015 to 253,620 cases in 2025 at an Annual Growth Rate (AGR) of 0.10%. In the 7MM, GlobalData epidemiologists forecast that the laparoscopy-confirmed diagnosed prevalent cases of endometriosis will increase from 6,160,839 cases in 2015 to 6,217,079 cases in 2025 at an AGR of 0.09%.
GlobalData epidemiologists utilized comprehensive, country-specific data from peer-reviewed journal articles, and primary research to arrive at a meaningful, in-depth analysis and forecast for laparoscopy-confirmed diagnosed incident cases of endometriosis, as well as laparoscopy-confirmed diagnosed prevalent cases of endometriosis. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of laparoscopy-confirmed diagnosed incident cases, and laparoscopy-confirmed diagnosed prevalent cases of endometriosis across these markets.
Scope
- The Endometriosis EpiCast Report provides an overview of the risk factors and global trends of endometriosis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the laparoscopy-confirmed diagnosed incident cases of endometriosis and a 10-year forecast of laparoscopy-confirmed diagnosed prevalent cases of endometriosis. Additional segmentations of patient populations are also available.
- The endometriosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Endometriosis EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
- Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometriosis therapeutics in each of the markets covered.
- Identify the distribution of endometriosis prevalent cases by
